Charles Craig

List of Publications by Year
in descending order

10 papers	145 citations	1307366 7 h-index	1474057 9 g-index
10 all docs	10 docs citations	10 times ranked	311 citing authors

#	Article	IF	Citations
1	Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 164-170.	0.9	38
2	Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. Aids, 2016, 30, 1229-1238.	1.0	34
3	Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor. Journal of Virology, 2015, 89, 11457-11472.	1.5	31
4	The maraviroc expanded access program â€" safety and efficacy data from an open-label study. HIV Clinical Trials, 2015, 16, 10-21.	2.0	11
5	Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials. PLoS ONE, 2018, 13, e0204099.	1.1	10
6	Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Pediatric Infectious Disease Journal, 2018, 37, 459-465.	1.1	9
7	Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naÃ¯ve HIV patients screened for Study A4001078. Antiviral Research, 2013, 97, 60-65.	1.9	7
8	Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials. Antiviral Chemistry and Chemotherapy, 2019, 27, 204020661989570.	0.3	4
9	Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc. Antiviral Chemistry and Chemotherapy, 2021, 29, 204020662110251.	0.3	1
10	V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1â€"infected, treatment-experienced persons receiving optimized background regimens. Antiviral Chemistry and Chemotherapy, 2021, 29, 204020662110303.	0.3	0